Clinical trials: Dapagliflozin
Adult Patients With Type 2 Diabetes Mellitus
XIGDUO Extended Release (XR) Post Marketing Surveillance
This is a local, prospective, non-interventional, regulatory postmarketing surveillance study. Adult patients with type 2 diabetes mellitus who are initiating Xigduo XR as indicated by the Ministry of Food and Drug Safety (MFDS)…
- Trial name
- XigduoPMS (NCT03038789)
- Where
- 8 sites in South Korea
- Volunteers
- 623 people
- Sponsor
- AstraZeneca
Acute Liver Injury
Acute Liver Injury in Patients on Dapagliflozin
To compare, by insulin use at the index date, the incidence of hospitalization for acute liver injury (ALI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695095
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 424,091 people
- Sponsor
- AstraZeneca
Antipsychotic-induced Weight Gain (AIWG), Antipsychotic-induced Weight Gain
Dapagliflozin Versus Metformin for the Management of Antipsychotic-Induced Weight Gain: A Pragmatic Pilot Randomized Controlled Trial
The goal of this clinical trial is to learn whether dapagliflozin can help manage weight gain caused by antipsychotic medications in people aged 16 years or older who are receiving antipsychotic treatment and have developed…
- Trial name
- NCT07342764
- Testing
- Dapagliflozin, Metformin, Common Lifestyle Program
- Where
- Oman
- Volunteers
- 110 people
- Sponsor
- Sultan Qaboos University
Dapagliflozin (Forxiga), Atrial Fibrillation (AF)
Dapagliflozin on Outcomes of Rhythm Control Strategy (Pharmacological ± Interventional) in Patient with Atrial Fibrillation
Investigator study the efficacy and safety outcomes of Dapagliflozin use among newly diagnosed Atrial fibrillation patients when underwent rhythm control strategy regardless their diabetic status.
- Trial name
- NCT06759909
- Testing
- Dapagliflozin (DAPA)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assiut University
Proteinuria, Chronic Kidney Diseases
Efficacy and Safety of Dapagliflozin in Children With Proteinuric Chronic Kidney Disease
We aim to investigate the antiproteinuric effect of adding Dapagliflozin to the standard of care in children with proteinuria.
- Trial name
- NCT04531397
- Testing
- ACEI treatment, Dapagliflozin+ACEI treatment
- Where
- China
- Sponsor
- Children's Hospital of Fudan University
Nephrotic Syndrome in Children
Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years
The goal of this clinical trial is to evaluate the effect of ACE inhibitors and SGLT-2 inhibitors on: 1. Proteinuria 2. Renal survival indices
- Trial name
- NCT06417320
- Testing
- ACEI, SGLT-2i
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Mansoura University
Acute Kidney Injury
Acute Kidney Injury in Patients on Dapagliflozin and Other Antidiabetic Medications
To compare, by insulin use at the index date, the incidence of hospitalization for acute kidney injury (AKI) among patients with type 2 diabetes mellitus who are new users of dapagliflozin with those who are new users of…
- Trial name
- NCT02695082
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 539,310 people
- Sponsor
- AstraZeneca
Heart Failure
Repurposing Empagliflozin and Dapagliflozin for Paediatric Heart Failure: Translational Approach and Dose Rationale
This study aims at exploring the use of Dapagliflozin and Empagliflozin in children and adolescents 6-18 years old with heart failure.
- Trial name
- NCT06012266
- Testing
- Dapagliflozin tablet, Empagliflozin Tablets
- Where
- 3 sites in Switzerland, United Kingdom
- Volunteers
- 12 people
- Sponsor
- Centre Hospitalier Universitaire Vaudois
Chronic Kidney Failure in Children and Young Adults
Phase 3 Clinical Trial With Dapagliflozin in Chronic Kidney Disease in Adolescents and Young Adult Patients
Recent trials have demonstrated positive renal outcomes of sodium-glucose co-transporter-2 inhibitors (SGLT2i) additive to angiotensin-converting-enzyme inhibitors (ACEis) in adult patients with diabetic and non-diabetic chronic…
- Trial name
- DOUBLE_PROTECT (NCT05944016)
- Testing
- Dapagliflozin
- Where
- 16 sites in Germany
- Volunteers
- 102 people
- Sponsor
- University Hospital Goettingen
Fontan, Heart Failure
The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure
While the Fontan operation improves survival for patients with a functional single ventricle, complications like heart failure remain prevalent during follow-up, causing frequent hospitalizations and reduced quality of life.
- Conditions
- Fontan, Heart Failure, Dapagliflozin, Cardiovascular Diseases
- Trial name
- NCT07482943
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
- Where
- 2 sites in Hong Kong
- Volunteers
- 30 people
- Sponsor
- The University of Hong Kong
Pulmonary Hypertension
Dapagliflozin in Mangement of Pulmonary Hypertension Patients
Effect of SGLT2 (Dapagliflozin)on prognosis of patient with pulmonary Hypertension and Effect on RV function By speckle tract echocardiography at Assiut University Hospital.
- Trial name
- NCT06612086
- Testing
- Dapagliflozin (Forxiga)
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Assiut University
Breast Cancer
Comparative Study Between (SGLT-2i) and (DPP-4i) in the Prevention of DIC
Background: Breast cancer is the most frequently diagnosed malignancy among women worldwide and a major cause of morbidity and mortality.
- Trial name
- SGLT2i/DPPi (NCT07436663)
- Testing
- Dapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy, Sitagliptin (DPP4 inhibitor), Standard Care (in control arm)
- Where
- Egypt
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Tanta University
Diabetes Mellitus, Type 2
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus (T2DM) Aged 10 to Below 18 Years Old
The primary objective of this study is to determine if there will be a greater mean reduction from baseline in glycated hemoglobin (HbA1c) achieved after 26 weeks of oral double-blind add-on therapy of dapagliflozin or…
- Trial name
- NCT03199053
- Testing
- Dapagliflozin, Saxagliptin
- Where
- 122 sites in United States, Argentina and 21 more
- Volunteers
- 256 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Liver Transplant; Complications
Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation
Patients with pre-transplantation type 2 diabetes (T2D) and new-onset diabetes post liver transplantation (NODAT) are managed with multiple doses of subcutaneous insulin (MSI) following liver transplantation.
- Trial name
- Dapa-LiT (NCT05042505)
- Testing
- Dapagliflozin 10Mg Tab, Sitagliptin 100mg
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Medanta, The Medicity, India
Diabetes Mellitus, Type 1
Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial
The ATTEMPT (Adolescent Type 1 diabetes Treatment with SGLT2i for hyperglycEMia \& hyPerfilTration Trial) is a multi-center, double-blinded, randomized, placebo-controlled trial to evaluate the effect of treatment with…
- Trial name
- ATTEMPT (NCT04333823)
- Testing
- Dapagliflozin 5mg
- Where
- 3 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- The Hospital for Sick Children
Chronic Kidney Disease (Mild to Moderate), Albuminuria
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease
Chronic kidney disease (CKD) is highly prevalent in the state of Aguascalientes, Mexico, particularly among adolescents and young adults.
- Conditions
- Chronic Kidney Disease (Mild to Moderate), Albuminuria, Adolescent, Sodium Glucose Co-Transporter 2 Inhibitors
- Trial name
- IECA-MEX (NCT07405216)
- Testing
- Dapagliflozin (10mg Tab)
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Centenario Hospital Miguel Hidalgo
Lung Cancer
SGLT2 Inhibitors and Survival in Lung Cancer Patients With Diabetes
The goal of this clinical trial The goal of this clinical trial is to evaluate whether SGLT2 inhibitor drugs can extend overall survival or delay the progression of the tumor in patients with both advanced lung cancer and…
- Trial name
- NCT07272057
- Testing
- SGLT-2 inhibitor
- Volunteers
- 200 people
- Sponsor
- Shanghai Chest Hospital
Diabetic Nephropathies, Diabetes Mellitus, Type 2
Comparing The Effect Of Empagliflozin With Dapagliflozin In Reducing Proteinuria In Diabetic Patients With Chronic Kidney Disease With eGFR More Than 45ml/Min/1.73m²
This study was designed to compare empagliflozin and dapagliflozin in reducing protein leakage into the urine in adults with type 2 diabetes and chronic kidney disease.
- Conditions
- Diabetic Nephropathies, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic
- Trial name
- NCT07866235
- Testing
- Dapagliflozin, Empagliflozin (EMPA)
- Where
- Pakistan
- Volunteers
- 116 people
- Sponsor
- Lahore General Hospital
Chronic Kidney Disease
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
This prospective observational study aims to assess the association between real-world use of sodium-glucose co-transporter 2 inhibitors (SGLT2i; e.g., empagliflozin, dapagliflozin) and renal function decline in adults with…
- Trial name
- NCT07348484
- Testing
- Empagliflozin
- Where
- Spain
- Volunteers
- 300 people
- Sponsor
- Instituto de Investigación Biomédica de Salamanca
Perioperative Complication
SGLT2 Inhibitors and Perioperative Period
The expanded use of SGLT2 inhibitors motivates us to assess the role of SGLT2 inhibitors in perioperative period on patients who will undergo cardiac surgery in Assiut University.
- Trial name
- NCT06326528
- Testing
- SGLT2 inhibitor
- Volunteers
- 100 people
- Sponsor
- Assiut University